Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy:: A phase 2 study

被引:61
作者
Krege, S [1 ]
Rembrink, V [1 ]
Börgermann, C [1 ]
Otto, T [1 ]
Rübben, H [1 ]
机构
[1] Univ Essen, Sch Med, Dept Urol, Essen, Germany
关键词
urinary tract; urothelium; carcinoma; transitional cell; ifosfamide; urologic neoplasms;
D O I
10.1097/00005392-200101000-00017
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: This phase 2 trial was designed to assess the efficacy and safety of combination chemotherapy with docetaxel and ifosfamide in previously treated patients with advanced urothelial cancer. Materials and Methods: Enrolled in our study were 22 patients with advanced urothelial cancer who failed to respond or had relapse after previous platinum based chemotherapy. Treatment consisted of 60 mg./m.(2) docetaxel given during 1 hour and 2.5 gm./m.(2) ifosfamide given for 24 hours every 3 weeks with 500 mg. mesna administered intravenously at the start of the ifosfamide infusion, and 4 and 8 hours later. Patients also received premedication with oral dexamethasone. Results: The objective response rate in 20 evaluable patients was 25%, including 4 complete responses (20%) associated with lymph node only recurrence. Disease was stable in 5 cases. At followup 16 patients had died 1 to 11 months (median 4) after the initiation of treatment, while 6 remained alive at 4 to 14 months, including 3 who were continuously disease-free. Treatment was well tolerated. Grades 3 and 4 leukopenia developed in 17% and 4% of the cycles, respectively. Neutropenic sepsis and grade 4 thrombocytopenia developed in 1 case each. Nausea and vomiting were mild to moderate. Other nonhematological toxicities included a hypersensitivity reaction in 1 patient and paresthesias in 2. Conclusions: The combination of docetaxel and ifosfamide is active in previously treated patients with urothelial cancer, although it appears to be a reasonable treatment option only in those with lymph node dominant recurrence. The mild toxicity underlines the usefulness of the regimen in this setting. Further investigation of the combination in previously untreated patients seems warranted.
引用
收藏
页码:67 / 71
页数:5
相关论文
共 19 条
[1]  
DELMURO XG, 1999, P AM SOC CLIN ONCOL, V18, P1306
[2]   Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel [J].
Dimopoulos, MA ;
Deliveliotis, C ;
Moulopoulos, LA ;
Papadimitriou, C ;
Mitropoulos, D ;
Anagnostopoulos, A ;
Athanassiades, P ;
Dimopoulos, C .
UROLOGY, 1998, 52 (01) :56-60
[3]  
FAIR WR, 1993, CANC PRINCIPLES PRAC
[4]   A RANDOMIZED COMPARISON OF CISPLATIN ALONE OR IN COMBINATION WITH METHOTREXATE, VINBLASTINE, AND DOXORUBICIN IN PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA - A COOPERATIVE GROUP-STUDY [J].
LOEHRER, PJ ;
EINHORN, LH ;
ELSON, PJ ;
CRAWFORD, ED ;
KUEBLER, P ;
TANNOCK, I ;
RAGHAVAN, D ;
STUARTHARRIS, R ;
SAROSDY, MF ;
LOWE, BA ;
BLUMENSTEIN, B ;
TRUMP, D .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (07) :1066-1073
[5]   A PROSPECTIVE RANDOMIZED TRIAL COMPARING MVAC AND CISCA CHEMOTHERAPY FOR PATIENTS WITH METASTATIC UROTHELIAL TUMORS [J].
LOGOTHETIS, CJ ;
DEXEUS, FH ;
FINN, L ;
SELLA, A ;
AMATO, RJ ;
AYALA, AG ;
KILBOURN, RG .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (06) :1050-1055
[6]   FLUOROURACIL AND RECOMBINANT HUMAN INTERFERON ALFA-2A IN THE TREATMENT OF METASTATIC CHEMOTHERAPY-REFRACTORY UROTHELIAL TUMORS [J].
LOGOTHETIS, CJ ;
HOSSAN, E ;
SELLA, A ;
DEXEUS, FH ;
AMATO, RJ .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (04) :285-288
[7]  
MARINI L, 1999, P AN M AM SOC CLIN, V18, P1335
[8]   Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma [J].
McCaffrey, JA ;
Hilton, S ;
Mazumdar, M ;
Sadan, S ;
Kelly, WK ;
Scher, HI ;
Bajorin, DF .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) :1853-1857
[9]  
MELUCH AA, 1999, P AN M AM SOC CLIN, V18, P1338
[10]   COMBINATION CISPLATIN AND DICHLOROMETHOTREXATE IN PATIENTS WITH ADVANCED BLADDER-CANCER - PHASE-2 - A SOUTHWEST ONCOLOGY GROUP-STUDY [J].
MEYERS, FJ ;
BLUMENSTEIN, B ;
CRAWFORD, ED ;
HYNES, HE ;
MONTIE, JE ;
TAYLOR, SA ;
GROSSMAN, HB ;
NATALE, RB .
JOURNAL OF UROLOGY, 1992, 148 (01) :52-54